Search Results
Mar 03, 2026, 07:15 ET ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
call.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Mar 02, 2026, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Company.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Mar 02, 2026, 16:05 ET Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
various additional undisclosed degraders.Highly differentiated, next-generation antibody drug conjugate (ADC) portfolio: Phase 1/2 study evaluating BHV-1510 (Trop2 ADC) as monotherapy and in combination with Regeneron's anti-PD-1 monoclonal antibody cemiplimab shows continued clinical
More news about: Biohaven Ltd.
Mar 01, 2026, 19:30 ET XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed
More news about: Antengene Corporation Limited
Feb 27, 2026, 04:11 ET WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
on net sales upon commercialization of any resulting ADC products.Leveraging its world-leading integrated CRDMO platform, WuXi XDC will also fully support the Chemical, Manufacturing, and Controls (CMC) development and manufacturing of the ADC components within the collaboration. Earendil Labs will
More news about: WuXi XDC
Feb 27, 2026, 02:00 ET Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform
on net sales upon commercialization of any resulting ADC products.Leveraging its world-leading integrated CRDMO platform, WuXi XDC will also fully support the Chemical, Manufacturing, and Controls (CMC) development and manufacturing of the ADC components within the collaboration. Earendil Labs will
More news about: Earendil Labs
Feb 26, 2026, 09:48 ET 再鼎醫藥公佈2025年第四季度及全年財務業績和近期公司進展
推進具有差異化優勢的全球管線，包括ZL-1503（IL-13/IL-31Rα）、ZL-6201（LRRC15 ADC）、ZL-1222（PD-1/IL-12）和ZL-1311（MUC17/CD3 TCE）– 持續推進關鍵區域性項目，KarXT在中國獲批並已啟動商業化上市籌備工作；
More news about: 再鼎醫藥
Feb 26, 2026, 09:17 ET Florida Cancer Specialists & Research Institute Advances Genitourinary Cancer Research at American Society of Clinical Oncology 2026 GU Symposium
director of drug development, SCRI at FCS, co-author: A phase 1/2, first-in-human study of AVZO-103, a bispecific Nectin4/Trop2 antibody-drug conjugate (ADC), as monotherapy and in combination therapy in patients with locally advanced or metastatic urothelial cancer (UC) or other solid tumors."Presenting
More news about: Florida Cancer Specialists & Research Institute
Feb 26, 2026, 08:00 ET Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences:TD Cowen 46th Annual Health Care Conference –
More news about: Whitehawk Therapeutics, Inc.
Feb 25, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
important milestone for IDE034 as well as our broader ADC/DDR portfolio focused on exploring combinations of highly selective TOP1 ADCs with agents targeting the DDR pathway. We are excited to begin dosing patients with IDE034, a B7H3/PTK7 bispecific ADC that has demonstrated promising signs of efficacy
More news about: IDEAYA Biosciences, Inc.
Feb 25, 2026, 03:37 ET Tong Hsing Electronic Partners with SixSense on AI Solutions
market evaluation. The partnership aims to advance Tong Hsing's smart factory initiatives, with an initial focus on AI-driven defect classification (ADC) in manufacturing processes.
More news about: Tong Hsing Electronic; SixSense Pte Ltd
Feb 24, 2026, 19:30 ET Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA
More news about: Antengene Corporation Limited
Feb 24, 2026, 07:15 ET ADC Therapeutics to Participate in March Investor Conferences
following.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Feb 23, 2026, 07:15 ET ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
www.ZYNLONTA.com.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Feb 18, 2026, 10:45 ET Ultra Maritime Awarded Development Contract for the Next Generation Acoustic Device Countermeasure
defense solutions has never been greater. Ultra Maritime has been awarded a development contract for the next generation Acoustic Device Countermeasure (ADC) MK6 from the U.S. Navy, to provide technology that can address these threats.
More news about: Ultra Maritime
Feb 18, 2026, 08:00 ET Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
More news about: Whitehawk Therapeutics, Inc.
Feb 17, 2026, 06:00 ET IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
OptimUM-01 trial in H1 '26 and H2 '26, respectively.Antibody-drug Conjugates (ADC) / DNA Damage Response (DDR) CombinationsIDE849 (DLL3 TOP1 ADC): targeting to provide a preliminary clinical data update from IDEAYA-sponsored global Phase 1 trial and
More news about: IDEAYA Biosciences, Inc.
Feb 13, 2026, 09:18 ET Precision Biologics' New PB-223 ADC Targeting Multiple Cancer Types to Be Highlighted in Keynote at 6th ACE Drug Discovery Summit
response to our PB-223 ADC with minimal toxicity in the preclinical animal studies. The target is found on a broad variety of human solid tumors but not on healthy tissue, suggesting a strong rationale to move this drug into clinical trials.""We're excited to discuss PB-223 ADC with the scientific
More news about: Precision Biologics
Feb 12, 2026, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
Derivative Conjugate, HER2 ADC) as a first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer. IBI354 has two pivotal Phase 3 trials ongoing (HeriCare-Ovarian01, HeriCare-Breast01), which holds potential to deliver a new generation of ADC therapies characterized
More news about: Innovent Biologics
Feb 12, 2026, 17:31 ET BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
the disease, historical and forecasted epidemiology, market share of the individual therapies, and key non-hodgkin's lymphoma companies, including ADC Therapeutics, Bristol-Myers Squibb, Roche, Amgen, Johnson & Johnson, Celgene Corp., Mesoblast, Genmab, Novartis, Teva Pharmaceutical Industries,
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 21:59 ET ACROBiosystems fördert Innovationen bei JPM Spotlight-Sessions von bioSeedin und unterstützt strategisch den Aufbau globaler Partnerschaften
Plattform-Iteration und Portfoliostrategie hin und prognostizierten für die kommenden Jahre weltweit wettbewerbsfähige Innovationen in den Bereichen ADC, TCE und neuartige Zell-/Gentherapie.Podium zu Herz-Kreislauf, Nieren und Stoffwechsel:Die Experten betonten, dass klinische Studien
More news about: ACROBiosystems Group
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
further create a positive impact on the market.Emerging ADC Landscape in EGFR-NSCLC: The ADC space in EGFR-NSCLC awaits more launches down the road, with several compounds under development in pivotal studies. The ADC space in EGFR-NSCLC awaits more launches down the road, with several
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 12:07 ET ACROBiosystems impulsa la innovación en JPM Spotlight de bioSeedin
fortalezas únicas de China en velocidad clínica, iteración de plataformas y estrategia de cartera, pronosticando innovaciones competitivas a nivel mundial en ADC, TCE y terapia celular/génica en los próximos años.Sesión cardio-renal-metabólica:Los expertos hicieron
More news about: ACROBiosystems Group
Feb 11, 2026, 04:01 ET Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and
More news about: Akeso, Inc.
Feb 11, 2026, 04:00 ET ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
Session:Panelists noted China's unique strengths in clinical speed, platform iteration and portfolio strategy, predicting globally competitive ADC, TCE and novel cell/gene therapy innovations in the coming years.Cardio-Renal-Metabolic Session:Experts stressed de-risking clinical
More news about: ACROBiosystems Group